At the time of writing, BridgeBio Pharma Inc [BBIO] stock is trading at $35.46, up 3.53%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBIO shares have gain 6.36% over the last week, with a monthly amount drifted -7.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $50. On October 03, 2024, Oppenheimer initiated with a Perform rating. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $46 on September 04, 2024. BMO Capital Markets started tracking with a Market Perform rating for this stock on January 31, 2024, and assigned it a price target of $37. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $58 on this stock.
For the past year, the stock price of BridgeBio Pharma Inc fluctuated between $21.62 and $39.54. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $35.46 at the most recent close of the market. An investor can expect a potential return of 103.05% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
According to BridgeBio Pharma Inc [NASDAQ:BBIO], the company’s sales were 127.42M for trailing twelve months, which represents an -44.76% plunge. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.29%, and Net Profit Margin reading is -5.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.49 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.55 points at the first support level, and at 33.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.94, and for the 2nd resistance point, it is at 36.43.
Ratios To Look Out For
It is important to note that BridgeBio Pharma Inc [NASDAQ:BBIO] has a current ratio of 4.57. Also, the Quick Ratio is 4.54, while the Cash Ratio stands at 3.55. Considering the valuation of this stock, the price to sales ratio is 52.84.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on May 20 ’25 when 75000.0 shares were sold. Chief Executive Officer, Kumar Neil completed a deal on May 19 ’25 to sell 26156.0 shares. Meanwhile, Director NEIL KUMAR bought 26156.0 shares on May 19 ’25.
